Sartorius doubles production capacity in UK with new facility
August 1, 2016Manufacturing and Production, Sales and Marketing Princess Anne, Sartorius, UK, expansion
Pharmaceutical and laboratory equipment provider Sartorius has expanded operations at its Stonehouse site in Gloucestershire with a new plant, doubling …
European Commission approves Zepatier for chronic hepatitis C infection
August 1, 2016Research and Development, Sales and Marketing
MSD, known as Merck in the US and Canada, has announced that the European Commission has approved Zepatier (elbasvir/grazoprevir) with …
Surprise for Seres as shares sent tumbling by Phase II failure
August 1, 2016Research and Development, Sales and Marketing FDA, clostrodium difficile, seres therapeutics
Seres Therapeutics has presented interim results from an ongoing Phase II trial which has sent company stock spiralling downward, as …
EMA accepts MMA for rheumatoid arthritis treatment Sarilumab
August 1, 2016Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …
GSK and Alphabet to create bioelectronics medicines in £540 million partnership
August 1, 2016Research and Development, Sales and Marketing Alphabet, GSK, Verily, bioelectronic medicine, galvani, google
GlaxoSmithKline and Verily Life Sciences, a division of Google’s parent company Alphabet, have announced a £540 million partnership that will …
FDA fast tracks Shire’s SHP626 nonalcoholic steatohepatitis drug
July 29, 2016Research and Development FDA, SHP626, Shire, liver fibrosis, nash, volixibat, volxibat
The Food and Drug Administration (FDA) has granted Fast Track designation to Shire’s SHP626 (volixibat) treatment for patients suffering from …
Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016
July 29, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo
Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …
China’s Fosun seals $1.3 billion deal for Gland Pharma
July 29, 2016Medical Communications, Sales and Marketing acquisition, fosun, gland, takeover
Fosun Pharmaceutical has agreed a deal to purchase an 86.1% stake of Gland Pharma, which will see the Chinese firm …
Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial
July 29, 2016Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis
Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …
Earnings drop at Sanofi as it looks for a quick Medivation resolution
July 29, 2016Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings
Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …
Roche urges reform of Cancer Drugs Fund as NICE takes control
July 29, 2016Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche
Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …
Ashfield provides clarity on the age old debate: ‘Syndicated’ or ‘Dedicated’ field sales?
July 28, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Ashfield is understandably well placed to offer a balanced viewpoint on field sales teams. With over 20 years of experience, …
Strong early data on haemophilia gene therapy boosts Biomarin
July 28, 2016Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a
Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …
Cholesterol drugs drag AstraZeneca’s profits down in latest financial results
July 28, 2016Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results
AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …
LMTX fails Phase III trial, monotherapy benefits seen
July 28, 2016Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure
TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …
Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin
July 28, 2016Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand
Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …
John Lechleiter to step down as Lilly CEO
July 27, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter
Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …
Shire and BMS secure NICE recommendations for oncology drugs
July 27, 2016Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
Orkambi deemed not suitable for NHS use
July 27, 2016Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis
The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …
Pharma unit helps boost profits at Bayer
July 27, 2016Research and Development, Sales and Marketing Bayer, Q2, results
The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
